| SCHEDULE OF RECONCILIATION OF PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company’s
reportable segment for the periods presented:
SCHEDULE
OF RECONCILIATION OF PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For The Three Months |
|
|
For The Nine Months |
|
| |
|
Ended September 30, |
|
|
Ended September 30, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue, net: |
|
$ |
8,756 |
|
|
$ |
12,295 |
|
|
$ |
29,504 |
|
|
$ |
34,515 |
|
| Less: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fixed |
|
|
1,736 |
|
|
|
1,801 |
|
|
|
5,120 |
|
|
|
4,999 |
|
| Variable |
|
|
1,581 |
|
|
|
2,592 |
|
|
|
6,298 |
|
|
|
7,497 |
|
| Operating and other expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sales and marketing |
|
|
2,087 |
|
|
|
2,864 |
|
|
|
7,811 |
|
|
|
8,571 |
|
| Research and development |
|
|
150 |
|
|
|
199 |
|
|
|
500 |
|
|
|
483 |
|
| General and administrative |
|
|
2,057 |
|
|
|
2,538 |
|
|
|
7,268 |
|
|
|
6,918 |
|
| Interest & other expense, net |
|
|
145 |
|
|
|
539 |
|
|
|
268 |
|
|
|
954 |
|
| (Benefit) provision for income taxes |
|
|
(11 |
) |
|
|
4 |
|
|
|
7 |
|
|
|
12 |
|
| Segment net income |
|
|
1,011 |
|
|
|
1,758 |
|
|
|
2,232 |
|
|
|
5,081 |
|
| Reconciliation of profit or loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss on discontinued operations |
|
|
(100 |
) |
|
|
(82 |
) |
|
|
(314 |
) |
|
|
(260 |
) |
|
Consolidated net income |
|
$ |
911 |
|
|
$ |
1,676 |
|
|
$ |
1,918 |
|
|
$ |
4,821 |
|
|
| SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA |
SCHEDULE
OF RECONCILIATION OF ADJUSTED EBITDA
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended |
|
|
Nine Months Ended |
|
| |
|
September 30, |
|
|
September 30, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Income from continuing operations (GAAP Basis) |
|
$ |
1,011 |
|
|
$ |
1,758 |
|
|
$ |
2,232 |
|
|
$ |
5,081 |
|
| Depreciation and amortization |
|
|
111 |
|
|
|
85 |
|
|
|
307 |
|
|
|
205 |
|
| Stock-based compensation |
|
|
7 |
|
|
|
86 |
|
|
|
31 |
|
|
|
218 |
|
| Severance & related expense |
|
|
- |
|
|
|
- |
|
|
|
692 |
|
|
|
- |
|
| Asset impairment - lab supplies |
|
|
- |
|
|
|
- |
|
|
|
198 |
|
|
|
- |
|
| Taxes (benefit) expense |
|
|
(11 |
) |
|
|
4 |
|
|
|
7 |
|
|
|
12 |
|
| Interest accretion expense |
|
|
- |
|
|
|
4 |
|
|
|
- |
|
|
|
34 |
|
| Note payable interest |
|
|
30 |
|
|
|
141 |
|
|
|
156 |
|
|
|
514 |
|
| Other expense/income, net |
|
|
10 |
|
|
|
(10 |
) |
|
|
25 |
|
|
|
(40 |
) |
| Change in fair value of note payable |
|
|
105 |
|
|
|
404 |
|
|
|
87 |
|
|
|
445 |
|
| Adjusted EBITDA |
|
$ |
1,263 |
|
|
$ |
2,472 |
|
|
$ |
3,735 |
|
|
$ |
6,469 |
|
|